Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
This article was originally published in The Tan Sheet
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
You may also be interested in...
GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.